Ivermectin inhibits importin-α/β-dependent nuclear import of viral proteins
66,68,69,75, shows spike-ACE2 disruption at 1nM with microfluidic diffusional sizing
33, binds to glycan sites on the SARS-CoV-2 spike protein preventing interaction with blood and epithelial cells and inhibiting hemagglutination
36,76, shows dose-dependent inhibition of wildtype and omicron variants
31, exhibits dose-dependent inhibition of lung injury
56,61, may inhibit SARS-CoV-2 via IMPase inhibition
32, may inhibit SARS-CoV-2 induced formation of fibrin clots resistant to degradation
5, inhibits SARS-CoV-2 3CL
pro49, may inhibit SARS-CoV-2 RdRp activity
24, may minimize viral myocarditis by inhibiting NF-κB/p65-mediated inflammation in macrophages
55, may be beneficial for COVID-19 ARDS by blocking GSDMD and NET formation
77, may inhibit SARS-CoV-2 by disrupting CD147 interaction
78-81, shows protection against inflammation, cytokine storm, and mortality in an LPS mouse model sharing key pathological features of severe COVID-19
54,82, may be beneficial in severe COVID-19 by binding IGF1 to inhibit the promotion of inflammation, fibrosis, and cell proliferation that leads to lung damage
4, may minimize SARS-CoV-2 induced cardiac damage
35,43, increases Bifidobacteria which play a key role in the immune system
83, has immunomodulatory
46 and anti-inflammatory
65,84 properties, and has an extensive and very positive safety profile
85.